Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BCellMax Life 〉CRC Protect

CRC Protect

CRC Protect

1.One minute, one blood sample, once a year
2.No messy stool samples, no radiation
3.Accurate, non-invasive early detection of colorectal cancer
4.Clinically proven
5.Innovative, advanced testing looks for cancer cells in the bloodstream

Request for Collaboration
Now with CRC Protect, you can offer all of your patients convenient and accurate CRC screening with a simple blood test.

Using just a blood sample, the CRC Protect can detect precancerous cells before they become tumors. CRC Protect helps you determine next steps for your patients and gives you confidence that you are  screening with an accurate, clinically proven test for early detection of colorectal cancer.

What are CTCs?
CTCs are cancer cells that detach from a primary tumor and circulate through the bloodstream and are a fundamental mechanism of metastasis. CTCs have long been known to be valuable in cancer detection, but most technologies using CTCs are only able to detect late-stage cancer. The CellMax CTC blood test “liquid biopsy” detects these CTCs in the blood at the earliest stages. This is one of the first clinical studies to show that CTCs can be useful for detecting early, more treatable stages of cancer. 
The researchers enrolled 620 people over the age of 20 who were either visiting the hospital for routine colonoscopies or had confirmed colorectal cancer. After a colonoscopy and biopsy, 438 people were found to have either adenomatous polyps (pre-cancerous growths) or early to late-stage colorectal cancer. The remaining study participants had no signs of pre-cancerous growths or colorectal cancer and were the comparison group.
Two milliliters (about half a teaspoon) of peripheral whole blood were tested from each subject for CTC analysis through a routine blood draw. The blood samples were then processed through the CMx platform. The results of these assays were then compared in a blinded analysis with the colonoscopy results.
The study results showed that the test's sensitivity ranged from 77 percent for detection of CTCs in pre-cancerous lesions to 87 percent for stage I-IV cancers. The accuracy of the results, taking into account both sensitivity and specificity, was high and ranged from 84 to 88 percent for pre-cancerous and cancerous samples. Additionally, the accuracy of this test was superior to that of fecal occult blood testing (FOBT), a guideline-recommended stool test for colorectal cancer screening.
“The positive results of this study prove that the CellMax CTC blood test can address the unmet need for a convenient and accurate test for early colorectal cancer detection; since the test only requires a routine blood draw, it can be easily integrated into a patient's regular physical exam, increasing compliance,” said study co-author Ashish Nimgaonkar, MD, a gastroenterologist and medical director at the Center for Bioengineering Innovation & Design at Johns Hopkins University.

“Early detection is perhaps the only real cure for cancer. To be effective, tests for early cancer detection need to be non-invasive, easy, highly affordable and accurate, and the CellMax CTC blood test meets all of these requirements,” said Atul Sharan, co-founder and CEO of CellMax Life. “Recent surveys reveal a preference for blood tests over stool-based screening tests in more than 80 percent of patients who did not undergo invasive colonoscopy screening. This test can be an option for these individuals and boost compliance.”
The data from the study, sponsored by Taiwan's Ministry of Health and its largest hospital, the Linkou Chang Gung Memorial Hospital, were presented by lead author, Dr. Wen-Sy Tsai (MD, Ph.D.) at the 2018 ASCO Gastrointestinal Cancers Symposium on Saturday, January 20.

The fundamental principle behind this recent breakthrough in early cancer detection relies on the CMxTM Platform's ability to find CTCs among billions of various normal cells in a blood sample—as soon as they enter the blood stream. With this new technology, early-stage cancer, and even pre-cancer, can be detected.  

Our proprietary platform- microfluidic chip, antibody, and imaging software- has enabled us to be the only company to overcome the “intractable” challenge of detecting rare CTCs in pre-cancer and early stage patients, when cancer can be successfully treated.

Those who meet below criteria  :
1. Those who want to take care of their own colorectal/intestinal health
2. Those who have higher risk taking colonscopy or anesthesia
3.  High risk of colorectal cancer :
    a. over 40 years old.
    b. family cancer history
    c. overweight
    d. eat out often
    e. drinking 
    f.  smoking
    g. sedentary lifestyle
    h. betel nut consumption
    i. excessive consumption of red meat
    j. excessive consumption of processed food

1. CRC Protect is not suited for everyone and is intended to be used in conjunction with other colorectal cancer screening modalities.
    a. Medical history of treated or untreated colorectal cancer polyps, colorectal cancer, or other gastrointestinal
    b. Medical history of inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease.
    c. Recent (past 6 months) positive colorectal cancer test results with other screening modalities.
    d. Patients who have had a colonoscopy or surgical procedure in the last 6 weeks.

Collaboration Options
Marketing & Distribution

More Information
People who like this also like
  • Proserpine PenProserpine Pen
  • SEDA Anti-Decubitus MattressSEDA Anti-Decubitus Mattress
  • Human 110 Specific IgG/IgE Screening Test (GE110)Human 110 Specific IgG/IgE Screening Test (GE110)
  • Anscare Healus Hydrogel dressingAnscare Healus Hydrogel dressing
  • Absorbable Adhesion BarrierAbsorbable Adhesion Barrier
  • Surgical InstrumentsSurgical Instruments
  • PhytoHealth EnerCharge® DrinkPhytoHealth EnerCharge® Drink
  • Linicor (Niacin 500mg/ Lovastatin 20mg)Linicor (Niacin 500mg/ Lovastatin 20mg)
  • Smart Baby SystemSmart Baby System
  • ProFlow®ProFlow®